Login / Signup

The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities.

Melanie HerpelsJun IshiharaAnguraj Sadanandam
Published in: The Journal of pathology (2023)
Pancreatic ductal adenocarcinoma (PDAC) is the most common and aggressive type of pancreatic cancer and has abysmal survival rates. In the past two decades, immunotherapeutic agents with success in other cancer types have gradually been trialled against PDACs at different stages of cancer progression, either as a monotherapy or in combination with chemotherapy. Unfortunately, to this day, chemotherapy still prolongs the survival rates the most and is prescribed in clinics despite the severe side effects in other cancer types. The low success rates of immunotherapy against PDAC have been attributed most frequently to its complex and multi-faceted tumour microenvironment (TME) and low mutational burden. In this review, we give a comprehensive overview of the immunotherapies tested in PDAC clinical trials thus far, their limitations, and potential explanations for their failure. We also discuss the existing classification of heterogenous PDACs into cancer, cancer-associated fibroblast, and immune subtypes and their potential opportunity in patient selection as a form of personalisation of PDAC immunotherapy. © 2023 The Pathological Society of Great Britain and Ireland.
Keyphrases
  • papillary thyroid
  • squamous cell
  • clinical trial
  • stem cells
  • machine learning
  • randomized controlled trial
  • primary care
  • squamous cell carcinoma
  • childhood cancer
  • case report
  • deep learning
  • risk assessment
  • early onset